Xeomin

What Xeomin does

XEOMIN (incobotulinumtoxinA) is an FDA-approved prescription injectable neurotoxin marketed by Merz North America, Inc., a wholly-owned U.S. subsidiary of the German pharmaceutical company Merz Pharma GmbH & Co. KGaA. The product is indicated for the temporary improvement of moderate to severe upper facial lines in adults — specifically glabellar frown lines (20 units), horizontal forehead lines (20 units), and lateral canthal crow's feet (24 units), with a maximum recommended simultaneous dose of 64 units. XEOMIN's core technical differentiator is XTRACT TECHNOLOGY, a proprietary double-filtered purification process that strips complexing proteins and bacterial remnants from the botulinum toxin type A preparation, yielding a final formulation of botulinum toxin type A, human albumin, and sucrose (0.44 ng clostridial protein per 100U versus 4.35–5.0 ng for competing toxins). The product is sold exclusively as a prescription pharmaceutical through licensed healthcare providers — dermatologists, plastic surgeons, aesthetic physicians, and medical spas — who order via the Merz Aesthetics Portal and administer treatments in their practices. The company employs a dual-channel go-to-market: enterprise-style field sales and provider acquisition on the professional side, paired with direct-to-consumer brand building (xeominaesthetic.com, Instagram, Find a Provider locator) that drives patients into the provider network. Revenue mechanics combine one-time wholesale product sales (50- and 100-unit vials) with the Xperience+ subscription-style loyalty program, which offers tiered provider rebates, semi-annual rebate cycles, and patient reward points redeemable across the broader Merz Aesthetics portfolio.

Name

Xeomin

Legal name

Merz North America, Inc.

Website

https://xeominaesthetic.com

Company type

Private

Founded year

1908

Operating status

Operating

Headcount range

11–50 employees

Short description

XEOMIN is an FDA-approved injectable neurotoxin (incobotulinumtoxinA) marketed by Merz North America for the temporary improvement of moderate to severe upper facial lines in adults, distributed exclusively through licensed dermatologists, plastic surgeons, and aesthetic practices using proprietary XTRACT TECHNOLOGY.

Ownership category

akta.pro rank

Product category

Aesthetic Neurotoxins

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Botulinum toxin injectable
• Aesthetic neurotoxin
• Prescription cosmetic injectable
• Facial line treatment
• Anti-wrinkle injection

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Technology or R&D, Supply Chain, Personnel

Revenue model

1. Pharmaceutical Product Sales: XEOMIN is sold as a prescription neurotoxin product to healthcare providers and aesthetic practices. Providers purchase vials (50 or 100 units) through the Merz Aesthetics Portal and administer treatments to patients in their practices. Revenue is generated from wholesale product sales to the provider network.
2. Xperience+ Loyalty Program: The Xperience+ rewards program provides tiered benefits including immediate discounts on purchases, rebate savings applied every 6 months, and patient reward points. Providers earn status tiers based on purchase volume, with higher tiers unlocking greater savings.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

XEOMIN (incobotulinumtoxinA) is a double-filtered botulinum toxin type A injectable prescription medicine used to temporarily improve the appearance of moderate to severe upper facial lines — glabellar frown lines, horizontal forehead lines, and lateral canthal lines (crow's feet) — in adults. It is sold in 50-unit and 100-unit vials and administered by licensed healthcare professionals via intramuscular injection. The product is supported by the Xperience+ patient rewards program offering savings, rebates, and loyalty points across the Merz Aesthetics portfolio.

Product overview

XEOMIN is a single FDA-approved aesthetic neurotoxin product (incobotulinumtoxinA) for temporary improvement of moderate to severe upper facial lines. It is manufactured by Merz North America, Inc. and is distributed through a provider network. The product features XTRACT TECHNOLOGY double-filtering to remove complexing proteins, and is offered alongside the Xperience+ loyalty rewards program for patients and providers.

Differentiator

Problem solved

Functional benefit

Brands

• Xperience+: Loyalty rewards program offering patients savings on XEOMIN treatments, with instant discounts, rebate savings, and points redeemable across the Merz Aesthetics portfolio.

Products and services

• XEOMIN (incobotulinumtoxinA) XEOMIN is a prescription, double-filtered botulinum toxin type A injectable administered by licensed healthcare professionals to temporarily improve moderate to severe upper facial lines (frown lines 20U, forehead lines 20U, crow's feet 24U) in adults. It is sold in 50-unit and 100-unit vials through the Merz Aesthetics Portal to dermatologists, plastic surgeons, aesthetic physicians, and medical spas, with results lasting approximately 3-4 months.
• Xperience+ Rewards Program Xperience+ is a tiered loyalty program offering patients $50 instant savings on their first treatment (limited to once every 90 days per patient), up to $240 annual savings on XEOMIN treatments, and points redeemable for savings on other Merz Aesthetics products and treatments. Providers also receive tiered benefits based on purchase volume, including immediate discounts on purchases and rebate savings applied every six months.

Quantifiable outcome

• 96% patient satisfaction rate based on clinical studies
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Merz North America, Inc.coreOthersMerz North America, Inc. is the U.S. subsidiary of Merz Pharma GmbH & Co. KGaA, the parent company and manufacturer of XEOMIN. The company handles U.S. distribution, marketing, and sales operations for the XEOMIN brand. Merz Aesthetics portfolio includes additional aesthetic products and treatments beyond XEOMIN.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Revance Therapeutics: Markets Daxxify (daxibotulinumtoxinA), a novel longer-duration botulinum toxin. Competes with XEOMIN in the same provider channel and patient indication, with a duration advantage that threatens XEOMIN's repeat-treatment model.
• Galderma: Markets Dysport (abobotulinumtoxinA), a competing botulinum toxin used for the same upper facial line indications as XEOMIN. Both products compete for the same provider channel and aesthetic patient segment.
• Allergan Aesthetics (AbbVie): Markets Botox (onabotulinumtoxinA), the dominant aesthetic and therapeutic botulinum toxin. Directly competes with XEOMIN in the same provider-administered facial line indication with a much larger installed base and brand recognition.
• Evolus: Markets Jeuveau (prabotulinumtoxinA), a newer aesthetic-only neurotoxin directly competing with XEOMIN for the same provider-administered facial line market with a focused commercial model.

Emerging players

• Medytox: South Korean developer of Meditoxin, a competing botulinum toxin with international regulatory approvals. Represents an emerging player in the same neurotoxin category as XEOMIN.
• Hugel: South Korean manufacturer of Botulax/Letybo (letibotulinumtoxinA), a botulinum toxin competing in global aesthetic markets. An emerging international peer to XEOMIN with growing U.S. and global footprint.
• Daewoong Pharmaceutical: South Korean manufacturer of Nabota (botulinum toxin type A), a competing aesthetic neurotoxin expanding internationally. An emerging peer in the same injectable neurotoxin category as XEOMIN.

Others

• Ipsen: Global pharmaceutical company that originally developed and distributes Dysport (abobotulinumtoxinA) in many markets. An adjacent ecosystem participant in the same botulinum toxin value chain that competes indirectly with XEOMIN.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• InstagramInstagram.com/xeominaesthetic
• Xx.com/XeominAesthetic

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xeomin